Helpt u ons aan 500 donateurs?

Nog een reden om donateur te worden als u extracten van medicinale paddenstoelen wilt gaan gebruiken misschien? Bij Oriveda krijgen onze donateurs 25% korting op extracten van medicinale paddensteolen.

1 maart 2018: zie ook dit artikel: 

https://kanker-actueel.nl/champignons-bewerkt-met-speciale-belichting-hebben-daarmee-veel-extra-vitamine-d-en-kunnen-vitamine-d-supplementen-vervangen.html

31 januari 2017: zie ook het abstract van een review studie uit 2012 over de waarde van PSK - polysaccharide K (KRESTIN(®) bij vele vormen van kanker klik op volgende link - Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): review of development and future perspectives - waaronder vooral ook bij vormen van spijsverteringskanker, zoals darmkanker, rectumkanker, maagkanker enz..

En zie ook: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study

En zie referentielijst onderaan dit artikel

Een persoonlijke opmerking hierbij: zouden alle mensen en organisaties die geld geven aan het KWF zich wel realiseren dat zelden of nooit geld gaat naar onderzoek naar dit soort niet toxische middelen en behandelingen?

12 januari 2010: Een paar belangrijke studies van effect van PSK geactualiseerd. Zie abstracten hieronder die duidelijk aangeven dat PSK significant beter werkt dan chemo bij darmkanker. Raadpleeg wel altijd een deskundig arts voor gebruik van medicinale paddestoelen.

1 december 2004: Bron: British Journal of Cancer 2004;90:1003-1010. en Int J Colorectal Dis 2004;19:157-164.

Twee verschillende langjarige gerandomiseerde Japanse studies wijzen uit dat PSK (krestin) significant betere resultaten, minder risico geeft op recidiefkansen en betere resultaten op de vijf-jaars overleving en op de definitieve overleving van darmkanker stadium II en III na operatie. Vooral ook de kansen op uitzaaiinge in de longen vanuit darmkanker werden met aanvulend PSK heel ver teruggedrongen en verminderd. Hoewel in de tweede studie die een follow-up kende van 7 jaar geen significant verschil was in ziektevrije periode binnen zeven jaar tussen beide groepen. Wel was er een positief en significant verschil in overlijden aan de kanker in de PSK groep in vergelijking met controlegroep die standaardbehandeling kreeg met chemo. PSK (krestin) is een stofje gehaald uit medicinale paddestoelen zoals Maitake enz. Van de eerste studie hebben we al dit voorjaar het abstract geplaatst, zie bij artikelenreeks over PSK. Hier de twee studies bij elkaar gezet en gehaald uit PUBMED omdat die in onderstaand artikel beide besproken worden.

Bron: British Journal of Cancer 2004;90:1003-1010.
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T, Morishita Y.
Department of Surgery, Gunma University, Graduate School of Medicine, Gunma Oncology Study Group (GOSG), 3-39-15 Showa-Machi, Maebashi 371-8511, Gunma, Japan. sohwada@med.gunma-u.ac.jp

Intravenous fluorouracil and leucovorin is the standard adjuvant treatment for stage III colon cancer. However, oral adjuvant chemotherapy is attractive because it has low toxicity and greater convenience. We investigated the benefits of oral protein-bound polysaccharide K (PSK) with tegafur/uracil (UFT) as an adjuvant in stage II and III colorectal cancer.

Patients were assigned to groups that received either 3 g PSK plus 300 mg UFT, or 300 mg UFT alone orally each day for a 2-year period following intravenous mitomycin C. Of 207 registered patients, 205 with stage II (n=123) or III (n=82) were analysed.

References belonging to the study Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer

References

  • Algarra I, Collado A, Garrido F. Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones. J Exp Clin Cancer Res. 1997;16:373–380. [PubMed]
  • Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20:3617–3627. [PubMed]
  • Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–766. [PMC free article] [PubMed]
  • Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20:3605–3616. [PubMed]
  • Ebina T, Murata K. Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents. Jpn J Cancer Res. 1992;83:775–782. [PubMed]
  • Feliu J, Gonzalez Baron M, Espinosa E, Garcia Giron C, de la Gandara I, Espinosa J, Colmenarejo A, Jalon JI, Fernandez Y, de Castro J. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Cancer. 1997;79:1884–1889. [PubMed]
  • Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, Marsili S, Aquino A, Marzocca G, Civitelli S, Mariani L, De Sando D, Bovenga S, Lorenzi M. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology. 1994;106:899–906. [PubMed]
  • Goldberg RM, Fleming TR, Tangen CM, Moertel CG, Macdonald JS, Haller DG, Laurie JA. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med. 1998;129:27–35. [PubMed]
  • Grage TB, Moss SE. Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial. Surg Clin North Am. 1981;61:1321–1329. [PubMed]
  • Harada M, Matsunaga K, Oguchi Y, Iijima H, Tamada K, Abe K, Takenoyama M, Ito O, Kimura G, Nomoto K. Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer. 1997;70:362–372. [PubMed]
  • Hayashida Y, Kurimoto S, Yamamoto N. Effect of lymphokine-activated killer cells on human retinoblastoma cells (Y-79) in vitro: enhancement of the activity by a polysaccharide preparation, krestin. Biochem Biophys Res Commun. 1991;174:107–114. [PubMed]
  • Higgins GA, Humphrey E, Juler G, LeVeen HH, McCaughan J, Keehn RJ. Adjuvant chemotherapy in the surgical treatment of large bowel cancer. Cancer. 1976;38:1461–1467. [PubMed]
  • Hirose K, Zachariae CO, Oppenheim JJ, Matsushima K. Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res. 1990;9:475–483. [PubMed]
  • IMPACT Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345:939–944. [PubMed]
  • Kato M, Hirose K, Hakozaki M, Ohno M, Saito Y, Izutani R, Noguchi J, Hori Y, Okumoto S, Kuroda D, Nomura H, Nishimatsu S, Ohoyanagi Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother. 1995;40:152–156. [PubMed]
  • Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 2001;61:1645–1651. [PubMed]
  • Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, Tollenaar RA. Micrometastases and survival in stage II colorectal cancer. N Engl J Med. 1998;339:223–228. [PubMed]
  • MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–460. [PubMed]
  • Malik ST, Talbot D, Clarke PI, Osborne R, Reznek R, Wrigley PF, Slevin ML. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer. 1990;62:1023–1025. [PMC free article] [PubMed]
  • Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, Amano T, Takahashi T, Murayama N, Oka H, Noto T, Ogawa N. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa) Dis Colon Rectum. 1992;35:123–130. [PubMed]
  • Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358. [PubMed]
  • Morinaga H, Tazawa K, Tagoh H, Muraguchi A, Fujimaki M. An in vivo study of hepatic and splenic interleukin-1 beta mRNA expression following oral PSK or LEM administration. Jpn J Cancer Res. 1994;85:1298–1303. [PubMed]
  • Nakazato H, Ito K, Takagi H, Saji S, Koike A, Baba S, Mai M, Ohashi Y, Sakamoto J. A randomized clinical trial on adjuvant immunochemotherapy with protein bound polysaccharide K (PSK) after curative resection of colon cancer. Proc Am Soc Clin Oncol. 1999;18:245a.
  • Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994;343:1122–1126. [PubMed]
  • O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ, Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16:295–300. [PubMed]
  • Ohwada S, Iino Y, Miyamoto Y. Adjuvant immunochemotherapy for colorectal cancer. Recent Adv Chemother. 1994. pp. G785–G789.
  • Okumura S, Kondo H, Tsuboi M, Nakayama H, Asamura H, Tsuchiya R, Naruke T. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg. 1996;112:867–874. [PubMed]
  • Pedrinaci S, Algarra I, Garrido F. Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res. 1999;29:135–140. [PubMed]
  • Porschen R, Bermann A, Loffler T, Haack G, Rettig K, Anger Y, Strohmeyer G. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol. 2001;19:1787–1794. [PubMed]
  • QUASAR Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet. 2000;355:1588–1596. [PubMed]
  • Rustum YM. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology. 1997;54:7–11. [PubMed]
  • Sakamoto J, Teramukai S, Koike A, Saji S, Ohashi Y, Nakazato H. Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. Cancer. 1996;77:2206–2212. [PubMed]
  • Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–914. [PubMed]
  • Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP. A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer. 1995;75:782–785. [PubMed]
  • Tamura K, Shibata Y, Matsuda Y, Ishida N. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res. 1981;41:3244–3252. [PubMed]
  • Tomizawa N, Ohwada S, Tanahashi Y, Ogawa T, Toru K, Izumi T, Ikeya T, Morishita Y. Prognostic factors after anatomical hepatectomy for liver metastases from colorectal cancer Hepatogastroenterologyin press
  • Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, Yamamoto H, Kimura Y, Takesue M, Kondo M, Nomoto K. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother. 1990;31:261–268. [PubMed]
  • Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG, Jr, Pinedo HM. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999;353:345–350. [PubMed]
  • Yefenof E, Gafanovitch I, Oron E, Bar M, Klein E. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother. 1995;41:389–396. [PubMed]
  • Zalcberg JR, Siderov J, Simes J. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. Ann Oncol. 1996;7:42–46. [PubMed]
  • Zhang H, Morisaki T, Matsunaga H, Sato N, Uchiyama A, Hashizume K, Nagumo F, Tadano J, Katano M. Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs. Clin Exp Metastasis. 2000;18:343–352. [PubMed]

Plaats een reactie ...

Reageer op "Darmkanker en PSK: PSK als aanvulling op de chemo's UFT en 5-FU geeft na operatie bij darmkanker stadium II en III significant betere resultaten op 5-jaars overleving en definitieve overleving en vermindert hoog significant longuitzaaiingen."


Gerelateerde artikelen
 

Gerelateerde artikelen

Darmkanker en effect van PSK: >> Darmkanker en PSK: PSK als >> Darmkanker: PSK als aanvulling >> Darmkanker: PSK - polysaccharide >> PSK en PSP studies - stofjes >>